◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

10-Q Filing

GUIDED THERAPEUTICS INC CIK: 924515 Q2 2011
Filing Information
Form Type 10-Q
Accession Number 0001121781-11-000340
Period End Date 20110630
Filing Date 20111114
Fiscal Year 2011
Fiscal Period Q2
XBRL Instance gthp-20110630.xml
Filing Contents

This filing contains the following financial statements:

Balance Sheet 72 line items
Line Item Tag Value Unit Period
Cash and cash equivalents CashAndCashEquivalentsAtCarryingValue $230.00K USD Point-in-time
Preferred stock, par value PreferredStockParOrStatedValuePerShare $0.00 USD Point-in-time
Preferred stock, par value PreferredStockParOrStatedValuePerShare $0.00 USD Point-in-time
Cash and cash equivalents CashAndCashEquivalentsAtCarryingValue $3.27M USD Point-in-time
Cash and cash equivalents CashAndCashEquivalentsAtCarryingValue $2.34M USD Point-in-time
Cash and cash equivalents CashAndCashEquivalentsAtCarryingValue $373.00K USD Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $38 at June 30, 2011 and December 31, 2010 AccountsReceivableNet $149.00K USD Point-in-time
Preferred stock, Authorized PreferredStockSharesAuthorized 5,000.00 shares Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $38 at June 30, 2011 and December 31, 2010 AccountsReceivableNet $85.00K USD Point-in-time
Preferred stock, Authorized PreferredStockSharesAuthorized 5,000.00 shares Point-in-time
Other current assets OtherAssetsCurrent $22.00K USD Point-in-time
Preferred stock, Issued PreferredStockSharesIssued 0.00 shares Point-in-time
Preferred stock, Issued PreferredStockSharesIssued 0.00 shares Point-in-time
Other current assets OtherAssetsCurrent $30.00K USD Point-in-time
Preferred stock, outstanding PreferredStockSharesOutstanding 0.00 shares Point-in-time
Total current assets AssetsCurrent $3.38M USD Point-in-time
Total current assets AssetsCurrent $2.51M USD Point-in-time
Preferred stock, outstanding PreferredStockSharesOutstanding 0.00 shares Point-in-time
Common stock, par value CommonStockParOrStatedValuePerShare $0.00 USD Point-in-time
Common stock, par value CommonStockParOrStatedValuePerShare $0.00 USD Point-in-time
Property and equipment, net PropertyPlantAndEquipmentNet $37.00K USD Point-in-time
Property and equipment, net PropertyPlantAndEquipmentNet $64.00K USD Point-in-time
Common stock, Authorized CommonStockSharesAuthorized 100,000.00 shares Point-in-time
Capitalized cost of internally developed software for internal use CapitalizedComputerSoftwareNet $409.00K USD Point-in-time
Capitalized cost of internally developed software for internal use CapitalizedComputerSoftwareNet $299.00K USD Point-in-time
Common stock, Authorized CommonStockSharesAuthorized 100,000.00 shares Point-in-time
Other Assets AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment $331.00K USD Point-in-time
Common stock, Issued CommonStockSharesIssued 47,299.00 shares Point-in-time
Other Assets AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment $200.00K USD Point-in-time
Common stock, Issued CommonStockSharesIssued 48,491.00 shares Point-in-time
Common stock, outstanding CommonStockSharesOutstanding 47,299.00 shares Point-in-time
Total noncurrent assets AssetsNoncurrent $804.00K USD Point-in-time
Common stock, outstanding CommonStockSharesOutstanding 48,491.00 shares Point-in-time
Total noncurrent assets AssetsNoncurrent $536.00K USD Point-in-time
Total assets Assets $3.32M USD Point-in-time
Total assets Assets $3.92M USD Point-in-time
Short-term debt ShortTermBorrowings $25.00K USD Point-in-time
Short-term debt ShortTermBorrowings $24.00K USD Point-in-time
Notes payable NotesPayable $162.00K USD Point-in-time
Notes payable NotesPayable - USD Point-in-time
Notes payable - past due NotesPayablePastDue $340.00K USD Point-in-time
Notes payable - past due NotesPayablePastDue $614.00K USD Point-in-time
Accounts payable AccountsPayableCurrent $937.00K USD Point-in-time
Accounts payable AccountsPayableCurrent $915.00K USD Point-in-time
Accrued liabilities AccruedLiabilities $885.00K USD Point-in-time
Accrued liabilities AccruedLiabilities $773.00K USD Point-in-time
Deferred revenue DeferredRevenue $655.00K USD Point-in-time
Deferred revenue DeferredRevenue $332.00K USD Point-in-time
Total current liabilities LiabilitiesCurrent $2.89M USD Point-in-time
Total current liabilities LiabilitiesCurrent $2.77M USD Point-in-time
Long-term debt payable, less current portion LongTermDebt $31.00K USD Point-in-time
Long-term debt payable, less current portion LongTermDebt $17.00K USD Point-in-time
Total Liabilities Liabilities $2.80M USD Point-in-time
Total Liabilities Liabilities $2.91M USD Point-in-time
Series A convertible preferred stock, $.001 par value; 5,000 shares authorized, no shares outstanding as of June 30, 2011 and December 31, 2010 PreferredStockValue - USD Point-in-time
Series A convertible preferred stock, $.001 par value; 5,000 shares authorized, no shares outstanding as of June 30, 2011 and December 31, 2010 PreferredStockValue - USD Point-in-time
Common stock, $.001 Par value; 100,000 shares authorized, 48,491 and 47,299 shares issued and outstanding as of June 30, 2011 and December 31, 2010, respectively CommonStockValue $48.00K USD Point-in-time
Common stock, $.001 Par value; 100,000 shares authorized, 48,491 and 47,299 shares issued and outstanding as of June 30, 2011 and December 31, 2010, respectively CommonStockValue $47.00K USD Point-in-time
Additional paid-in capital AdditionalPaidInCapital $79.52M USD Point-in-time
Additional paid-in capital AdditionalPaidInCapital $80.03M USD Point-in-time
Treasury stock, at cost TreasuryStockValue $-104.00K USD Point-in-time
Treasury stock, at cost TreasuryStockValue $-104.00K USD Point-in-time
Accumulated deficit RetainedEarningsAccumulatedDeficit $-79.67M USD Point-in-time
Accumulated deficit RetainedEarningsAccumulatedDeficit $-78.44M USD Point-in-time
Total Guided Therapeutics stockholders' equity StockholdersEquityBeforeNoncontrollingInterest $1.01M USD Point-in-time
Total Guided Therapeutics stockholders' equity StockholdersEquityBeforeNoncontrollingInterest $306.00K USD Point-in-time
Non-controlling interest NoncontrollingInterest $104.00K USD Point-in-time
Non-controlling interest NoncontrollingInterest $104.00K USD Point-in-time
Total stockholders' equity StockholdersEquity $410.00K USD Point-in-time
Total stockholders' equity StockholdersEquity $1.12M USD Point-in-time
Total liabilities and stockholders' equity LiabilitiesAndStockholdersEquity $3.32M USD Point-in-time
Total liabilities and stockholders' equity LiabilitiesAndStockholdersEquity $3.92M USD Point-in-time
Income Statement 60 line items
Line Item Tag Value Unit Period
Service revenue Revenues $1.68M USD 2 Qtrs
Service revenue Revenues $805.00K USD 1 Quarter
Service revenue Revenues $1.63M USD 2 Qtrs
Service revenue Revenues $913.00K USD 1 Quarter
Research and development ResearchAndDevelopmentExpense $490.00K USD 1 Quarter
Research and development ResearchAndDevelopmentExpense $619.00K USD 1 Quarter
Research and development ResearchAndDevelopmentExpense $1.31M USD 2 Qtrs
Research and development ResearchAndDevelopmentExpense $897.00K USD 2 Qtrs
Sales and marketing SellingAndMarketingExpense $78.00K USD 2 Qtrs
Sales and marketing SellingAndMarketingExpense $44.00K USD 1 Quarter
Sales and marketing SellingAndMarketingExpense $120.00K USD 2 Qtrs
Sales and marketing SellingAndMarketingExpense $71.00K USD 1 Quarter
General and administrative GeneralAndAdministrativeExpense $1.28M USD 2 Qtrs
General and administrative GeneralAndAdministrativeExpense $708.00K USD 1 Quarter
General and administrative GeneralAndAdministrativeExpense $1.47M USD 2 Qtrs
General and administrative GeneralAndAdministrativeExpense $802.00K USD 1 Quarter
Total costs and expenses CostsAndExpenses $2.90M USD 2 Qtrs
Total costs and expenses CostsAndExpenses $1.40M USD 1 Quarter
Total costs and expenses CostsAndExpenses $2.29M USD 2 Qtrs
Total costs and expenses CostsAndExpenses $1.34M USD 1 Quarter
Operating loss OperatingIncomeLoss $-628.00K USD 2 Qtrs
Operating loss OperatingIncomeLoss $-485.00K USD 1 Quarter
Operating loss OperatingIncomeLoss $-531.00K USD 1 Quarter
Operating loss OperatingIncomeLoss $-1.23M USD 2 Qtrs
Other income OtherIncome $7.00K USD 1 Quarter
Other income OtherIncome $44.00K USD 2 Qtrs
Other income OtherIncome - USD 1 Quarter
Other income OtherIncome - USD 2 Qtrs
Interest expense InterestExpense $-1.30M USD 2 Qtrs
Interest expense InterestExpense $-41.00K USD 2 Qtrs
Interest expense InterestExpense $-18.00K USD 1 Quarter
Interest expense InterestExpense $-28.00K USD 1 Quarter
Loss from operations IncomeLossFromContinuingOperations $-1.22M USD 2 Qtrs
Loss from operations IncomeLossFromContinuingOperations $-1.93M USD 2 Qtrs
Loss from operations IncomeLossFromContinuingOperations $-496.00K USD 1 Quarter
Loss from operations IncomeLossFromContinuingOperations $-559.00K USD 1 Quarter
Provision for income taxes IncomeTaxReconciliationOtherReconcilingItems - USD 2 Qtrs
Provision for income taxes IncomeTaxReconciliationOtherReconcilingItems - USD 2 Qtrs
Provision for income taxes IncomeTaxReconciliationOtherReconcilingItems - USD 1 Quarter
Provision for income taxes IncomeTaxReconciliationOtherReconcilingItems - USD 1 Quarter
Net loss NetIncomeLoss $-1.93M USD 2 Qtrs
Net loss NetIncomeLoss $-559.00K USD 1 Quarter
Net loss NetIncomeLoss $-1.22M USD 2 Qtrs
Net loss NetIncomeLoss $-496.00K USD 1 Quarter
Preferred stock dividends DividendsPreferredStock - USD 1 Quarter
Preferred stock dividends DividendsPreferredStock - USD 1 Quarter
Preferred stock dividends DividendsPreferredStock $-1.70M USD 2 Qtrs
Preferred stock dividends DividendsPreferredStock - USD 2 Qtrs
Net loss attributable to common stockholders NetIncomeLossAttributableToCommonStockholders $-496.00K USD 1 Quarter
Net loss attributable to common stockholders NetIncomeLossAttributableToCommonStockholders $-3.63M USD 2 Qtrs
Net loss attributable to common stockholders NetIncomeLossAttributableToCommonStockholders $-1.22M USD 2 Qtrs
Net loss attributable to common stockholders NetIncomeLossAttributableToCommonStockholders $-559.00K USD 1 Quarter
Basic and diluted net loss per share attributable to common stockholders NetIncomeLossPerShareAttributableToCommonStockholdersBasicAndDiluted $0.13 USD 2 Qtrs
Basic and diluted net loss per share attributable to common stockholders NetIncomeLossPerShareAttributableToCommonStockholdersBasicAndDiluted $0.03 USD 2 Qtrs
Basic and diluted net loss per share attributable to common stockholders NetIncomeLossPerShareAttributableToCommonStockholdersBasicAndDiluted $0.02 USD 1 Quarter
Basic and diluted net loss per share attributable to common stockholders NetIncomeLossPerShareAttributableToCommonStockholdersBasicAndDiluted $0.01 USD 1 Quarter
Weighted average shares outstanding WeightedAverageNumberOfSharesOutstandingBasic 48,159.00 shares 2 Qtrs
Weighted average shares outstanding WeightedAverageNumberOfSharesOutstandingBasic 26,969.00 shares 2 Qtrs
Weighted average shares outstanding WeightedAverageNumberOfSharesOutstandingBasic 48,464.00 shares 1 Quarter
Weighted average shares outstanding WeightedAverageNumberOfSharesOutstandingBasic 32,520.00 shares 1 Quarter
Cash Flow Statement 64 line items
Line Item Tag Value Unit Period
Net loss NetIncomeLoss $-1.93M USD 2 Qtrs
Net loss NetIncomeLoss $-559.00K USD 1 Quarter
Net loss NetIncomeLoss $-1.22M USD 2 Qtrs
Net loss NetIncomeLoss $-496.00K USD 1 Quarter
Depreciation and amortization DepreciationAndAmortization $2.00K USD 2 Qtrs
Depreciation and amortization DepreciationAndAmortization $8.00K USD 2 Qtrs
Amortization and accretion of deferred financing costs, notes and warrants AmortizationOfFinancingCosts - USD 2 Qtrs
Amortization and accretion of deferred financing costs, notes and warrants AmortizationOfFinancingCosts $1.09M USD 2 Qtrs
Stock based compensation ShareBasedCompensation $470.00K USD 2 Qtrs
Stock based compensation ShareBasedCompensation $251.00K USD 2 Qtrs
Gain on debt renegotiated GainOnDebtRenigotiated $-23.00K USD 2 Qtrs
Gain on debt renegotiated GainOnDebtRenigotiated - USD 2 Qtrs
Accounts receivable IncreaseDecreaseInAccountsReceivable $31.00K USD 2 Qtrs
Accounts receivable IncreaseDecreaseInAccountsReceivable $-64.00K USD 2 Qtrs
Other assets IncreaseDecreaseInOtherOperatingAssets $57.00K USD 2 Qtrs
Other assets IncreaseDecreaseInOtherOperatingAssets $-131.00K USD 2 Qtrs
Accounts payable IncreaseDecreaseInAccountsPayable $-8.00K USD 2 Qtrs
Accounts payable IncreaseDecreaseInAccountsPayable $-22.00K USD 2 Qtrs
Deferred revenue IncreaseDecreaseInDeferredRevenue $323.00K USD 2 Qtrs
Deferred revenue IncreaseDecreaseInDeferredRevenue $278.00K USD 2 Qtrs
Accrued liabilities IncreaseDecreaseInAccruedLiabilities $-41.00K USD 2 Qtrs
Accrued liabilities IncreaseDecreaseInAccruedLiabilities $153.00K USD 2 Qtrs
Other current assets IncreaseDecreaseInOtherCurrentAssets - USD 2 Qtrs
Other current assets IncreaseDecreaseInOtherCurrentAssets $8.00K USD 2 Qtrs
Total adjustments AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities $2.08M USD 2 Qtrs
Total adjustments AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities $309.00K USD 2 Qtrs
Net cash (used in) provided by operations NetCashProvidedByUsedInContinuingOperations $-913.00K USD 2 Qtrs
Net cash (used in) provided by operations NetCashProvidedByUsedInContinuingOperations $147.00K USD 2 Qtrs
Additions to capitalized software CapitalizedComputerSoftwareAdditions $-11.00K USD 2 Qtrs
Additions to capitalized software CapitalizedComputerSoftwareAdditions $-110.00K USD 2 Qtrs
Additions to fixed assets AdditionsToNoncurrentAssets $-35.00K USD 2 Qtrs
Additions to fixed assets AdditionsToNoncurrentAssets $-86.00K USD 2 Qtrs
Net cash (used in) investing activities NetCashProvidedByUsedInInvestingActivities $-145.00K USD 2 Qtrs
Net cash (used in) investing activities NetCashProvidedByUsedInInvestingActivities $-97.00K USD 2 Qtrs
Proceeds from issuance of convertible notes payable to former debt holders - related parties ProceedsFromIssuanceOfConvertibleNotesRelatedParty - USD 2 Qtrs
Proceeds from issuance of convertible notes payable to former debt holders - related parties ProceedsFromIssuanceOfConvertibleNotesRelatedParty $101.00K USD 2 Qtrs
Proceeds from exercise of options and warrants ProceedsFromWarrantExercises - USD 2 Qtrs
Proceeds from exercise of options and warrants ProceedsFromWarrantExercises $195.00K USD 2 Qtrs
Payments on notes and loans payable PaymentsOfLoanCosts $-8.00K USD 2 Qtrs
Payments on notes and loans payable PaymentsOfLoanCosts $-62.00K USD 2 Qtrs
Net cash provided by financing activities NetCashProvidedByUsedInFinancingActivities $133.00K USD 2 Qtrs
Net cash provided by financing activities NetCashProvidedByUsedInFinancingActivities $93.00K USD 2 Qtrs
Net change in cash and cash equivalents CashAndCashEquivalentsPeriodIncreaseDecrease $-925.00K USD 2 Qtrs
Net change in cash and cash equivalents CashAndCashEquivalentsPeriodIncreaseDecrease $143.00K USD 2 Qtrs
Cash and cash equivalents, beginning of period CashAndCashEquivalentsAtCarryingValue $230.00K USD Point-in-time
Cash and cash equivalents, beginning of period CashAndCashEquivalentsAtCarryingValue $3.27M USD Point-in-time
Cash and cash equivalents, beginning of period CashAndCashEquivalentsAtCarryingValue $2.34M USD Point-in-time
Cash and cash equivalents, beginning of period CashAndCashEquivalentsAtCarryingValue $373.00K USD Point-in-time
Cash and cash equivalents, end of period CashAndCashEquivalentsAtCarryingValue $230.00K USD Point-in-time
Cash and cash equivalents, end of period CashAndCashEquivalentsAtCarryingValue $3.27M USD Point-in-time
Cash and cash equivalents, end of period CashAndCashEquivalentsAtCarryingValue $2.34M USD Point-in-time
Cash and cash equivalents, end of period CashAndCashEquivalentsAtCarryingValue $373.00K USD Point-in-time
Cash paid for Interest InterestPaid $1.00K USD 2 Qtrs
Cash paid for Interest InterestPaid $8.00K USD 2 Qtrs
Conversion of preferred stock into common stock ConversionOfPreferredStockIntoCommonStock $1.96M USD 2 Qtrs
Conversion of preferred stock into common stock ConversionOfPreferredStockIntoCommonStock - USD 2 Qtrs
Dividends payable in the form of preferred stock converted into common stock DividendsPayablePreferredStockConvertedToCommonStock - USD 2 Qtrs
Dividends payable in the form of preferred stock converted into common stock DividendsPayablePreferredStockConvertedToCommonStock $1.82M USD 2 Qtrs
Conversion of notes payable into common stock ConversionOfNotesPayableToCommonStock $27.00K USD 2 Qtrs
Conversion of notes payable into common stock ConversionOfNotesPayableToCommonStock $9.35M USD 2 Qtrs
Deemed dividends in the form of preferred stock and redeemable convertible preferred stock DividendsPreferredStockAndRedeemableConvertiblePreferredStock $1.70M USD 2 Qtrs
Deemed dividends in the form of preferred stock and redeemable convertible preferred stock DividendsPreferredStockAndRedeemableConvertiblePreferredStock - USD 2 Qtrs
Conversion of interest to principal ConversionOfInterestToPrincipal $23.00K USD 2 Qtrs
Conversion of interest to principal ConversionOfInterestToPrincipal - USD 2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.

NEWS
Loading news...
TRENDING
Loading...